Laboratory of Morphometry, Metabolism, and Cardiovascular Diseases, Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
Endocrine. 2019 Aug;65(2):252-262. doi: 10.1007/s12020-019-01969-y. Epub 2019 Jun 3.
To verify whether the treatment with linagliptin induces the browning of the subcutaneous WAT (sWAT) and thermogenesis in murine diet-induced obesity (DIO) model.
Forty animals were randomly assigned to receive a control diet (C, 10% lipids as energy) or a high-fat diet (HF, 50% lipids as energy) for 10 weeks. Each group was re-divided to begin the 5-week treatment, totalizing four experimental groups: C, C-L (C plus linagliptin, 30 mg/kg body mass; BM), HF, and HF-L (HF plus linagliptin, 30 mg/kg BM). The drug was mixed with diet.
HF animals showed overweight, glucose intolerance, and a greater cross-sectional area of adipocytes. The treatment with linagliptin was able to normalize the BM, restore the glucose tolerance and the cross-sectional area of adipocytes. These observations comply with the observation of UCP1-positive multilocular adipocytes in the sWAT of treated animals. Both treated groups (C-L and HF-L) showed high expression of thermogenic and type 2 cytokines genes, which agree with the enhanced body temperature and the lower respiratory exchange ratio, implying enhanced thermogenesis with the use of lipids as fuel.
The reduced BM, the enhanced body temperature, and the presence of positive UCP1 beige cells in the sWAT point to the activation of the browning cascade on the sWAT of linagliptin-treated mice, and hence, linagliptin could induce the thermogenic pathway as a pleiotropic effect that can have translational potential.
验证利拉利汀治疗是否能诱导肥胖小鼠皮下白色脂肪组织(sWAT)的褐变和产热。
40 只动物随机分为对照组(C 组,10%脂肪作为能量)或高脂肪饮食组(HF 组,50%脂肪作为能量),分别喂养 10 周。每组再分为两组,分别给予 5 周的治疗,共分为 4 个实验组:C 组、C 加利拉利汀组(C 加利拉利汀,30mg/kg 体重)、HF 组和 HF 加利拉利汀组(HF 加利拉利汀,30mg/kg 体重)。药物与饮食混合。
HF 组动物超重、葡萄糖耐量受损,脂肪细胞横截面积增大。利拉利汀治疗能使体重正常化,恢复葡萄糖耐量和脂肪细胞横截面积。这些观察结果与治疗动物 sWAT 中 UCP1 阳性多房脂肪细胞的观察结果一致。两种治疗组(C 加利拉利汀组和 HF 加利拉利汀组)均表现出高表达的产热和 2 型细胞因子基因,这与体温升高和呼吸交换率降低相一致,提示脂肪作为燃料的产热增强。
体重减轻、体温升高以及 sWAT 中 UCP1 阳性 beige 细胞的存在表明,利拉利汀治疗可激活 sWAT 中的褐变级联反应,从而诱导产热途径,这可能是其多效性作用的一种表现,具有转化潜力。